Monte Rosa Therapeutics (GLUE) Current Assets (2020 - 2026)

Monte Rosa Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $677.5 million for Q1 2026.

• On a quarterly basis, Current Assets rose 103.91% year-over-year to $677.5 million in Q1 2026; TTM through Mar 2026 was $677.5 million, a 103.91% increase from a year earlier, with the FY2025 full-year figure at $393.2 million, up 4.17% from the prior year.
• Current Assets rose to $677.5 million in Q1 2026 per GLUE's latest filing, from $393.2 million in the prior quarter.
• Across five years, Current Assets topped out at $677.5 million in Q1 2026 and bottomed at $182.9 million in Q3 2023.
• The 5-year median for Current Assets is $295.2 million (2022), against an average of $309.8 million.
• Across the five-year window, Current Assets sank 38.05% in 2023 and surged 103.91% in 2026, its largest moves.
• Year by year, Current Assets stood at $275.9 million in 2022, then slipped by 14.38% to $236.2 million in 2023, then jumped by 59.79% to $377.4 million in 2024, then gained by 4.17% to $393.2 million in 2025, then surged by 72.32% to $677.5 million in 2026.
• Per Business Quant, the three latest GLUE Current Assets figures stand at $677.5 million (Q1 2026), $393.2 million (Q4 2025), and $401.8 million (Q3 2025).